Study Title and Description
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.
Key Questions Addressed
|9||Key Question 9 - Probiotic or prebiotic interventions for prevention of initial and recurrent CDI|
Primary Publication Information
|Title||Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.|
|Author||Surawicz CM., Elmer GW., Speelman P., McFarland LV., Chinn J., van Belle G.|
|Country||Department of Medicine, University of Washington, Seattle.|
Pubmed ID: 2494098
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Question 4 - Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (Table 20)
|Question... Follow Up||Answer||Follow-up Answer|
|Country / Study Design||United States Randomized controlled trial|
|Sample||318 hospitalized patients given new antibiotics 180 completed study, 138 had C. difficile tested Mean age: 46.5 years Gender: Male 69%|
|Prevention of initial or recurrent Clostridium difficile infection?||Primary Prevention of Initial Clostridium difficile infection|
|Intervention/Comparison and Method||Probiotic: Sacchromyces boulardii (250 mg capsule with 1 g S. boulardii bid (n=116) Placebo bid (n=64) Stools collected for CD culture at entry, day 5 then q 10 d, end of study, and when have diarrhea (diarrhea 3 loose/watery stools/s x 2 d); CD culture + stools were tested for cytotoxin; need 3 stools tested for CD and 8 days of monitoring for inclusion|
|C. difficile Diarrhea (Diarrhea and CD Toxin +)||Overall incidence of Clostridium difficile infection: Probiotic: 3/116 (2.6%) Placebo: 5/64 (7.8%) Fisher’s Exact test performed by reviewers p=0.13 Incidence of diarrhea in 48 patients had stools that were CD toxin+: Probiotic: 3/32 (9.4%) Placebo: 5/16 (31%), test of significance between groups p=0.07|
|Later Recurrence of CD Diarrhea|
|Notes of Study Quality and Side Effects||Allocation concealment: not defined Blinding: double Intention-to-treat analysis*: no, 138 not evaluated (43%) Withdrawals and dropouts adequately described: yes|
Results & Comparisons
No Results found.